Jackson Hole Capital Partners LLC Buys 3,670 Shares of CVS Health Co. (NYSE:CVS)

Jackson Hole Capital Partners LLC increased its stake in shares of CVS Health Co. (NYSE:CVS) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,560 shares of the pharmacy operator’s stock after acquiring an additional 3,670 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in CVS Health were worth $3,203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of CVS. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 4.9% in the 4th quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after buying an additional 133 shares during the period. Apella Capital LLC lifted its holdings in CVS Health by 4.2% in the 4th quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock worth $272,000 after buying an additional 136 shares during the period. Prairie Sky Financial Group LLC lifted its holdings in CVS Health by 4.1% in the 4th quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock worth $285,000 after buying an additional 141 shares during the period. WealthShield Partners LLC lifted its holdings in CVS Health by 3.2% in the 4th quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock worth $355,000 after buying an additional 141 shares during the period. Finally, Sugarloaf Wealth Management LLC lifted its holdings in CVS Health by 9.5% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock worth $129,000 after buying an additional 142 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Down 0.7 %

CVS stock traded down $0.45 on Thursday, reaching $67.32. 8,915,583 shares of the company traded hands, compared to its average volume of 10,708,336. CVS Health Co. has a one year low of $64.41 and a one year high of $83.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The company has a market cap of $84.86 billion, a P/E ratio of 10.42, a price-to-earnings-growth ratio of 0.91 and a beta of 0.52. The firm has a fifty day simple moving average of $74.61 and a 200-day simple moving average of $73.67.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. The business had revenue of $93.81 billion during the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.99 EPS. Research analysts anticipate that CVS Health Co. will post 8.31 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date of this dividend is Friday, April 19th. CVS Health’s payout ratio is 41.18%.

Insiders Place Their Bets

In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CVS shares. SVB Leerink started coverage on CVS Health in a report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price objective for the company. StockNews.com cut CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Royal Bank of Canada lowered their target price on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research note on Thursday, February 8th. Wells Fargo & Company lowered their target price on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 8th. Finally, Barclays started coverage on CVS Health in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price for the company. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.44.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.